Sarah leads a synergistic research programme in neurodegeneration from basic cellular mechanisms of protein misfolding (using prions as a model tool) to translational clinical research. Sarah has had a major research interest in Huntington’s disease (HD) since her PhD, and Sarah’s team is spearheading a major effort to develop and test new disease-modifying therapies for HD. Her work leading TRACK-HD, an international study to understand the neurobiology of HD, has already identified biomarkers of disease progression that track the earliest phase of the neurodegenerative disease process in clinically-well individuals who carry the HD expansion mutation and those with early disease symptoms. Her work at the laboratory level aims to translate these approaches to patients within the next few years. Sarah also identified a key role for the innate immune system in the pathogenesis of HD that has given rise to important new avenues for research into biomarkers and disease-modifying therapies for HD. Sarah’s research programme is translating HD research directly from the lab to patients with a programme that is ultimately aimed at preventing the neurodegenerative disease process itself.